Last reviewed · How we verify

FLUIDDA nv — Portfolio Competitive Intelligence Brief

FLUIDDA nv pipeline: 1 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Placebo of Roflumilast Placebo of Roflumilast marketed
Placebo of Test product Placebo of Test product phase 3
Seretide Evohaler Seretide Evohaler phase 3 Corticosteroid and long-acting beta2-adrenergic receptor agonist combination Beta2-adrenergic receptor Respiratory
Placebo of Reference product Placebo of Reference product phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 1 shared drug class
  2. Chiesi Farmaceutici S.p.A. · 1 shared drug class
  3. Pearl Therapeutics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for FLUIDDA nv:

Cite this brief

Drug Landscape (2026). FLUIDDA nv — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fluidda-nv. Accessed 2026-05-15.

Related